XML 57 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies - License Agreement with Cardiff (Details)
9 Months Ended
Aug. 05, 2013
shares
Mar. 27, 2007
USD ($)
item
Mar. 31, 2017
USD ($)
Contribution Agreement      
Agreement      
Shares issued for assets (in shares) | shares 9,000,000    
Percentage of outstanding shares of common stock upon issuance 100.00%    
License Agreement | Cardiff      
Agreement      
Written notice period   90 days  
Default or breach cure period   90 days  
Late payment period   1 month  
Number of occasions in 12 month period | item   2  
First written notice period   120 days  
Royalty threshold rate (as a percent)   30.00%  
Second written notice period   90 days  
Counterparty's default or cure period   90 days  
Initial base payment made   $ 270,000  
Aggregate milestone payment   400,000  
Milestone payment upon initiation of phase 3 clinical trial   150,000  
Milestone payment upon approval of drug application   250,000  
License Agreement | BMS      
Agreement      
Aggregate milestone payment   9,000,000  
Initial base payment   1,000,000  
Milestone payment upon receiving marketing approval   3,000,000  
Milestone payment upon achieving net sales threshold   6,000,000  
Net sales threshold amount   $ 125,000,000  
Milestone payments     $ 0
Amounts accrued related to the payments     $ 0